ERBB2 and colorectal carcinoma: Similarly, in cetuximab-resistant CRC cell lines, the synergic antiproliferative effect of the anti-HER2 and anti-EGFR agent combinations (e.g., trastuzumab plus lapatinib or trastuzumab plus cetuximab) was demonstrated [115,131,132].